PD5-1-8: 4D CT imaging impacts lung volume definitions and dose-volume relationships in radiation treatment of non-small cell lung cancer  by Kang, Yixiu et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS474
orthogonal movements, of the nodal areas was initially 5.7 mm ± 2.9 
mm, which was somewhat smaller than the tumor motion (7.8 mm ± 
4.8 mm). The motion of the lymph nodes decreased during therapy (5.8 
mm after 1 week and 5.3 mm after 2 weeks) but was not statistically 
signiﬁcant different. No difference in motion and motion changes was 
observed between the locations of the lymph nodal areas.
Conclusion: A large variability of changes in nodal volume between 
the patients was observed, but is not clinically relevant since the vol-
umes and hence the volume changes are small. The motion of the nodal 
areas is smaller than the tumor motion and does not change during 
therapy. Therefore smaller internal margins can be applied for the nodal 
areas compared to the internal margin for the primary tumor.
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4D CT imaging impacts lung volume definitions and dose-volume 
relationships in radiation treatment of non-small cell lung cancer
Kang, Yixiu; Bucci, M. Kara; Liao, Zhongxing; Liu, Helen H.; Tucker, 
Susan L.; Chang, Joe Y.; Komaki, Ritsuko; Cox, James D.; Mohan, 
Radhe; Dong, Lei 
M.D. Anderson Cancer Center, Houston, TX, USA
Purpose: To characterize lung volume deﬁnitions at various CT 
imaging conditions for advanced non-small-cell lung cancer (NSCLC) 
patients. Due to respiratory motion, lung volumes measured by CT im-
aging can exhibit signiﬁcant volumetric variations, which can affect the 
assessment of dose-volume relationships for radiotherapy. The goal of 
this study was to quantify the range of uncertainties in the dose-volume 
relationships and suggest a uniﬁed correction procedure. 
Methods: Forty stage III/IV NSCLC patients were randomly selected 
for this study. For all patients, a fast CT scan and a 4D CT scan were 
acquired under natural breathing conditions. The fast CT scan (free 
breathing, or FB) represents the typical clinical practice for CT-based 
radiotherapy treatment planning. The 4D CT scan represents the state-
of-art volumetric imaging technique to explicitly include respiratory 
motion. We deﬁne the lung volumes measured in 4D CT at the end of 
inspiration and at the end of expiration as end inspiratory volume (EIV) 
and end expiratory volume (EEV), respectively. The percent of vol-
umes at 5Gy (V5), 20Gy (V20), and 50Gy (V50) were calculated and 
compared for each volume deﬁnition at FB, EEV, EIV, and a specially 
computed average density volume from 4D CT. 
Results: The total lung EIV was on average 13.9% larger than the EEV 
(1SD 5.1%; range: 5.7% to 28%). While the average density of the 
lung at the end of inspiration was 8% lower than the density of the lung 
at the end of expiration, the total mass enclosed in the lung volume 
was 4.6% higher at the end of inspiration than at the end of expira-
tion, possibly due to the blood inﬂow caused by the negative pressure. 
There was an excellent linear relationship between the density ratio 
and the volume ratio at the two breathing extremes among all patients 
(R=0.86; p<0.0001). We found a strong volume impact to the dose-vol-
ume relationship. The V5, V20, and V50 between EIV and EEV varied 
from -15% to +12%, -21% to +17%, and -6% to +3%, respectively. 
The V5, V20, and V50 deﬁned on FB CT scans were systematically 
smaller than those deﬁned in EEV (average=-1.9% for V5; -1.3% for 
V20; and -0.8% for V50) and varied signiﬁcantly (range from -12% to 
+1%), representing the uncertainties in the dose-volume analysis. These 
variations were primary due to volume differences at different breath-
ing phases. The impact of dose distribution by anatomy changes was 
minimal (V5, V20, and V50 variations were less than 1% for the same 
volume deﬁnition). We found that the use of a simple scaling factor can 
effectively correct or convert the dose-volume parameters from one 
phase to another using the population data obtained in this study.
Conclusions: Signiﬁcant variations in dose-volume parameters were 
found in current practice when using different volume deﬁnitions. 
We recommend reporting dose-response data on standardized volume 
deﬁnitions (such as the end of expiration, which is more nature for indi-
vidual patients). Parameters found in this study can be used to convert 
these dose-volume parameters from one volume deﬁnition to another 
based on population average.
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Effective local control of stage III non-small cell lung cancer 
(NSCLC) with accelerated radiotherapy for patients with 
unfavorable prognostic factors
Ohnishi, Kayoko; Komaki, Ritsuko; Alen, Pamela; Cox, James; Wei, 
Xiong; Liao, Zhongxing 
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Purpose: This retrospective study was performed to evaluate the ef-
ﬁcacy and toxicity of accelerated radiotherapy for patients with Stage 
III NSCLC with unfavorable prognostic factors (PF). 
Materials and Methods: Between 1994 and 2004, 113 patients with 
Stage III NSCLC and unfavorable PF were treated with accelerated 
radiotherapy of 45 Gy in 15 fractions over 3 weeks at the University of 
Texas M.D. Anderson Cancer Center. To compare the efﬁcacy of accel-
erated radiotherapy with conventional radiotherapy, 222 patients with 
Stage III NSCLC who received conventional radiotherapy of >60 Gy 
between 1987 and 2005 were identiﬁed. Their medical and radiological 
records were retrospectively reviewed and analyzed for overall survival 
(OS), local-regional control (LRC), disease free survival (DFS) and 
distant metastasis-free survival (DMFS). Acute and late toxicity of 
accelerated radiotherapy with regard to esophagus and lung were also 
analyzed.
Results: Compared to the patients treated with conventional radio-
therapy, the patients treated with accelerated radiotherapy were older 
in age, had poorer PF and received less chemotherapy. The median 
age was 67 (P<0.00001), 91 patients (81%) had a weight loss of >10% 
(P<0.0001) and 43 patients (38%) had Karnofsky performance status 
(KPS) <70 (P<0.0001). 75 patients (66%) received no chemotherapy. 
Median follow-up was 10 months for the accelerated group and 13 
months for the conventional radiotherapy group. OS was statistically 
